Treatment of ebola virus infection with antibodies from reconvalescent donors

Emerging Infectious Diseases

Volumn 21, Issue 3, 2015, Pages 521-523

  Kreil, Thomas R ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; DETERGENT; RIBOFLAVIN; SOLVENT; ANTISERUM; VIRUS ANTIBODY;

ARTICLE; BLOOD TRANSFUSION; CELL FRACTIONATION; DISEASE TRANSMISSION; DONOR; EBOLA HEMORRHAGIC FEVER; HEMOPHILIA; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE DEFICIENCY; INFLUENZA A; NONHUMAN; PATHOGEN REDUCTION SYSTEM; PLASMA TRANSFUSION; PLASMAPHERESIS; RECONVALESCENT DONOR; ULTRAVIOLET A RADIATION; VIRUS INACTIVATION; BLOOD DONOR; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; PLASMA;

ANTIBODIES, VIRAL; BLOOD DONORS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNE SERA; PLASMA;

EID: 84923172303     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2103.141838     Document Type: Article

References (15)

1. Mupapa K, Massamba M, Kibadi K, Kuvala K, Bwaka A, Kipasa M, et al.; International Scientifc and Technical Committee. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis. 1999;179(Suppl 1):S18–23. http://dx.doi.org/10.1086/514298
2. Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE, et al. Postexposure antibody prophylaxis protects nonhuman primates from flovirus disease. Proc Natl Acad Sci U S A. 2012;109:5034–9. http://dx.doi.org/10.1073/pnas.1200409109
3. Schlenke P. Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother. 2014;41:309–25. http://dx.doi.org/10.1159/000365646
4. Busch MP. Transfusion-transmitted viral infections: building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesis. Transfusion. 2006;46:1624–40. http://dx.doi.org/10.1111/j.1537-2995.2006.00957.x
5. Schmidt M, Korn K, Nübling CM, Chudy M, Kress J, Horst HA, et al. First transmission of human immunodefciency virus type 1 by a cellular blood product after mandatory nucleic acid screening in Germany. Transfusion. 2009;49:1836–44. http://dx.doi.org/10.1111/j.1537-2995.2009.02203.x
6. Montgomery SP, Brown JA, Kuehnert M, Smith TL, Crall N, Lanciotti RS, et al. The 2003 West Nile Virus Transfusion-Associated Transmission Investigation Team. Transfusion-associated transmission of West Nile virus, United States, 2003 through 2005. Transfusion. 2006;46:2038–46. http://dx.doi.org/10.1111/j.1537-2995.2006.01030.x
7. Kreil TR, Berting A, Kistner O, Kindermann J. West Nile virus and the safety of plasma derivatives: verifcation of high safety margins, and the validity of predictions based on model virus data. Transfusion. 2003;43:1023–8. http://dx.doi.org/10.1046/j.1537-2995.2003.00496.x
8. Sierra Leone Action. Sierra Leone Action receives donation of transfusion medicine equipment from Fresenius Kabi [cited 2014 Dec 1]. http://www.fresenius-kabi.com/fles/Sierra_Leone_Action_ Press_Release.pdf
9. Sobarzo A, Groseth A, Dolnik O, Becker S, Lutwama JJ, Perelman E, et al. Profle and persistence of the virus-specifc neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu). J Infect Dis. 2013;208:299–309. http://dx.doi.org/10.1093/infdis/jit162
10. Leroy EM, Baize S, Volchkov VE, Fisher-Hoch SP, Georges-Courbot MC, Lansoud-Soukate J, et al. Human asymptomatic Ebola infection and strong infammatory response. Lancet. 2000;355:2210–5. http://dx.doi.org/10.1016/S0140-6736(00)02405-3
11. Liumbruno GM, Franchini M. Solvent/detergent plasma: pharmaceutical characteristics and clinical experience. J Thromb Thrombolysis. 2014. Epub 2014 May 21. http://dx.doi.org/10.1007/s11239-014-1086-1
12. Dichtelmüller HO, Biesert L, Fabbrizzi F, Gajardo R, Gröner A, von Hoegen I, et al. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion. 2009;49:1931–43. http://dx.doi.org/10.1111/j.1537-2995.2009.02222.x
13. Burnouf T, Emmanuel J, Mbanya D, El-Ekiaby M, Murphy W, Field S, et al. Ebola: a call for blood transfusion strategy in sub-Saharan Africa. Lancet. 2014;384:1347–8. http://dx.doi.org/10.1016/S0140-6736(14)61693-7
14. El-Ekiaby M, Sayed MA, Caron C, Burnouf S, El-Sharkawy N, Goubran H, et al. Solvent-detergent fltered (SD-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. Transfus Med. 2010;20:48–61. http://dx.doi.org/10.1111/j.1365-3148.2009.00963.x
15. Kreil TR, Mc Vey JK, Lei LS, Camacho L, Wodal W, Kerschbaum A, et al. Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 infuenza. Transfusion. 2012;52:803–9. http://dx.doi.org/10.1111/j.1537-2995.2011.03347.x